Biolife Solutions Inc Dossier - Source-backed chat

Biolife Solutions Inc

BLFSNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.60

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $36.78Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.8B

Enterprise Value $1.8B

Shares Outstanding 50.4M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioLife Solutions is a highly strategic, high-margin pure-play provider of biopreservation media (CryoStor and HypoThermosol) for the rapidly growing cell and gene therapy (CGT) market. Following the successful divestiture of its non-core, lower-margin freezer and cold-chain equipment businesses, the company has transitioned into a high-margin, recurring-revenue model. With its media embedded in over 70% of active US clinical trials and 17 unique commercial therapies, BioLife enjoys an exceptionally strong competitive moat due to high switching costs and strict regulatory requirements. The company's return to GAAP profitability in Q1 2026 and robust cash position of $111.5 million provide a solid foundation for sustained double-digit growth and margin expansion.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$31.00

Mean target$31.29

High · most bullish analyst$33.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$26.0015%

Slower-than-expected clinical trial progression, delays in FDA approvals for customer therapies, or prolonged manufacturing yield issues compress gross margins to the low-60% range. Increased competition from broad life-science tools providers limits market share gains in adjacent segments.

Base CaseCentral scenario

$31.2960%

Matches the consensus mean

BioLife successfully executes on its reiterated 2026 guidance, delivering revenue of $112.5 million to $115.0 million (17% to 20% growth) and maintaining gross margins in the mid-60% range. The company remains GAAP net income positive for the full year, supported by steady clinical trial progression and commercial therapy expansions.

Bull CaseUpside scenario

$34.0025%

Accelerated commercial approvals of customer cell and gene therapies, combined with rapid resolution of temporary manufacturing yield issues, drive gross margins back to the high-60% range. Strong operating leverage pushes adjusted EBITDA margins above 28%, and revenue exceeds the high end of guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dominant market share (>70%) in biopreservation media for US clinical trials, creating a highly sticky, recurring revenue stream.
High switching costs as products are specified into FDA regulatory filings, making substitution by customers extremely difficult.
Successful strategic pivot to a high-margin, asset-light business model following non-core divestitures.
Strong balance sheet with $111.5 million in cash and marketable securities and minimal debt.

Key Investment Risks

Customer concentration risk, where delays or failures in major customer clinical trials directly impact media demand.
Temporary manufacturing yield issues that can cause short-term gross margin volatility.
Dependence on the broader funding environment and capital expenditure cycles of the biotechnology and CGT sectors.

Thesis Invalidation Triggers

Loss of market share in late-stage (Phase III) clinical trials to emerging biopreservation media competitors.
A significant drop in GAAP gross margins below 60% due to persistent manufacturing or supply chain issues.
Failure to achieve full-year GAAP net income profitability in 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.